Prior notification of a concentration (Case M.10004 - EQT/Zentricity/Cajelo/Recipharm) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 29/04
Date: 2021-01-26
Institutions: Directorate-General for Competition, European Commission
Subjects: economic concentration, investment company, logistics, merger control, packaging, pharmaceutical industry








C_2021029EN.01000401.xml










26.1.2021   


EN


Official Journal of the European Union


C 29/4






Prior notification of a concentration
(Case M.10004 - EQT/Zentricity/Cajelo/Recipharm)
Candidate case for simplified procedure
(Text with EEA relevance)
(2021/C 29/04)

1.   
On 18 January 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


EQT IX Collect EUR SCSp and EQT IX Collect USD SCSp (together ‘EQT IX’), part of the EQT group of private equity funds (‘EQT’, Luxembourg);










—


Zentricity Holding AB (‘Zentricity’, Sweden);










—


Cajelo Invest Ltd (‘Cajelo’, Cyprus); and










—


Recipharm AB (‘Recipharm’, Sweden).




EQT, Zentricity and Cajelo acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Recipharm.
The concentration is accomplished by way of public bid announced on 14 December 2020.


2.   
The business activities of the undertakings concerned are:






—


for EQT: private equity funds that invest in companies across the world, which amongst others control EQT IX, an investment fund investing primarily in Europe, with a focus on Northern Europe;










—


for Zentricity: investment company focusing on investing in pharmaceutical companies primarily in Sweden, which is controlled by private individual Thomas Eldered, who also controls the pharmaceutical companies Empros Pharma AB, Flerie Creations Ltd. and Flerie Invest AB;










—


for Cajelo: investment company which is controlled by private individual Lars Backsell, who also controls Glims Marketing Ltd. and Rohirrim AB, a horse breeding company.










—


for Recipharm: contract development and manufacturing organization, providing drug development and manufacturing services globally to the pharmaceutical industry (e.g. for finished dose pharmaceuticals, active pharmaceutical ingredients and clinical trial materials for customers in the pharmaceutical industry), as well as packaging services and logistics services.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10004 – EQT/Zentricity/Cajelo/Recipharm
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.